HUSH Restriction in HIV Infected Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04172480

Enrollment

Registered

2019-11-21

Start date

2019-10-01

Completion date

2023-09-30

Last updated

2021-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Brief summary

HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the Human Silencing Hub or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase SET domain bifurcated 1 (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.

Interventions

OTHERBlood sampling

Peripheral blood sampling on EDTA

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 80 Years

Healthy volunteers

Inclusion criteria

for group 1: * Symptomatic or asymptomatic acute HIV1 infection * Age above 15 years old * No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure) Inclusion Criteria for group 2: * Chronic HIV1 infection * Age above 18 years old * No ARV treatment since at least 3 month (regardless the reason) Inclusion Criteria for group 3: * HIV2 Infection * Age above 18 years old * No ARV treatment since at least 3 month (regardless the reason)

Exclusion criteria

for all groups: * HIV1 and HIV2 co-infection * Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV, tuberculosis, HTLV1) * Life-threatening pathology

Design outcomes

Primary

Measure	Time frame	Description
Viremia	Baseline	Intracellular HIV RNA load expressed in number of copies / ml
Total HIV DNA and integrated HIV DNA	Baseline	Quantification by qPCR
Hush activity	Baseline	Transcription rate of cellular genes targeted by HUSH by qRT-PCR

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026